Hematology Reports

4 pages, 458 KiB

Open AccessCase Report

Morphologic and Immunophenotypic Features of a Case of Acute Monoblastic Leukemia with Unusual Positivity for Glycophorin-A

by Giovanni Carulli, Paola Sammuri, Cristiana Domenichini, Martina Rousseau, Virginia Ottaviano, Maria Immacolata Ferreri, Antonio Azzarà, Francesco Caracciolo and Mario Petrini

Hematol. Rep. 2018, 10(4), 7823; https://doi.org/10.4081/hr.2018.7823 - 12 Dec 2018

Cited by 4 | Viewed by 394

Abstract

Acute monoblastic leukemia (AMoL) is characterized by cells with highly undifferentiated morphology. Cytochemistry with non-specific esterases is negative in up to 20% of cases. Immunophenotyping by flow cytometry has an essential role in diagnosing such a subtype of leukemia and a multiparametric approach with a wide monoclonal antibody panel is necessary. We describe a case of AMoL with morphology resembling either plasma blasts or very immature erythroblasts. Diagnosis was made by alpha-naphtyl-acetate esterase staining and with immunophenotyping, which was made with a wide monoclonal antibody panel. Blasts were positive for monocytic markers. Most of leukemic cells, however, were positive for Glycophorin-A. The presence of Glycophorin-A, which is considered as a specific marker of the erythroid lineage, has never been reported previously in cases of AMoL. This peculiar immunophenotype might be interpreted as deriving from a common myelo-erythroid precursor undergone leukemic transformation. Full article

2 pages, 326 KiB

Open AccessCase Report

Pulmonary Embolism in a Patient with Neuroleptic Malignant Syndrome

by Mosaad Almegren

Hematol. Rep. 2018, 10(4), 7753; https://doi.org/10.4081/hr.2018.7753 - 12 Dec 2018

Cited by 2 | Viewed by 378

Abstract

Venous thromboembolism is one of the complications in patients prescribed antipsychotic medications. Neuroleptic malignant syndrome (NMS) is a rare side effect of antipsychotic medications in this population. In this case, a young patient, who presented with NMS after a recent start of antipsychotic medications, had developed a pulmonary embolism despite standard of care measures of venous thromboprophylaxis and early mobilization. A low threshold of VTE suspicion and effective preventive measures are both required in order to avoid this preventable complication in this population. Full article

5 pages, 361 KiB

Open AccessReview

Transfusion-Associated Graft-Versus-Host Disease: A Concise Review

by Palma Manduzio

Hematol. Rep. 2018, 10(4), 7724; https://doi.org/10.4081/hr.2018.7724 - 6 Nov 2018

Cited by 18 | Viewed by 687

Abstract

Transfusion-associated graft-versus-host disease (TA-GVHD) represents a rare fatal event observed in immunocompromised patients and immunocompetent individuals. The main clinical features of this transfusion reaction are pancitopenia and multiorgan failure (skin, liver, gut). The possible pathogenesis includes donor T lymphocyte proliferation in blood, their engraftment and host tissue attack. The purpose of this narrative review was analyzing the international guidelines for irradiation of cellular blood components to prevent TA-GVHD. A literature search was conducted using PubMed articles published between January 2000 to July 2018. American, Australian, British and Japanese transfusion guidelines have been compared regarding clinical indications. The contribution of manuscripts has been focused on recipients of Haematopoietic Stem Cell Transplantation, severe cellular immunodeficient patients, fetuses and neonates, immunocompentent individuals. Furthermore, 348 cases of TA-GVHD in the last five decades have been documented according to a recent systematic review. The standard of care to prevent this complication is gamma or x irradiation of cellular blood products. New treatments with pathogen inactivation appear safe and effective against proliferating white blood cells and T cells. Further clinical and biological studies are necessary to better characterize immunocompetence of T cells and select alternative preventive strategies. Full article

2 pages, 311 KiB

Open AccessCase Report

Immunosuppression-Associated Posterior Reversible Encephalopathy Syndrome in an Acute Leukemia Case

by Umit Y. Malkan, Gursel Gunes, Haluk Demiroglu and Hakan Goker

Hematol. Rep. 2018, 10(4), 7257; https://doi.org/10.4081/hr.2018.7257 - 6 Nov 2018

Cited by 3 | Viewed by 353

Abstract

Posterior reversible encephalopathy syndrome (PRES) was described in 1996. Herein, we aimed to report an immunosuppression- related PRES case. A 34-year-old woman was diagnosed as t-cell acute lymphoblastic leukemia and allogeneic hematopoietic stem cell transplantation (HSCT) was performed. Cyclosporine was given for GVHD prophylaxis in addition to the other routine medications of HSCT. She was hospitalized for acute renal failure and due to the possible contribution of acute renal failure cyclosporine was stopped. Tacrolimus was started for GVHD prophylaxis at a dose of 1 mg/day. However, fifteen days after the initiation of tacrolimus, blurred vision occurred in our patient. Petechial bleeding sites were detected in bilateral cerebral and cerebellar hemisphere by MR imaging. Tacrolimus dosage was reduced to 0.5 mg/day. She had hypertension which was difficult to control and followed-up in the intensive care unit. She had seizures. Control cranial MR resulted as diffusion limitation in bilateral cerebellar hemisphere, bilateral occipital and frontal-parietal regions with vasogenic edema findings; contrast involvement in left frontal-parietal and right cerebellar regions. She had vision loss and lethargy. Control cranial MR favored PRES syndrome secondary to immunosuppression. Hypertensive state was taken under control with antihypertensive treatment and all immunosuppressive agents were stopped. Two weeks later her clinical condition was slightly improved. MR test which was conducted 2 weeks after the diagnosis revealed the regression of PRES lesions. The characteristic signs on neuroimaging are the symmetrical white matter edema in the posterior cerebral hemispheres, particularly the parietal- occipital regions. In conclusion, PRES rarely develops secondary to the immunosuppressive agents and the clinicians should suspect and promptly diagnose PRES which might cause otherwise serious irreversible clinical complications. Full article

Journal Menu

Journal Browser

Hematol. Rep., Volume 10, Issue 4 (November 2018) – 4 articles

Further Information

Guidelines

MDPI Initiatives

Follow MDPI